Please provide your email address to receive an email when new articles are posted on . At 52 weeks, MASH resolution without worsening of fibrosis was reported among 36% on denifanstat vs. 13% on ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy), an ...

Please provide your email address to receive an email when new articles are posted on . Among patients with FIB-4 nonalcoholic steatohepatitis at greater risk for progression to end stage liver ...

SAN MATEO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...

Efruxifermin significantly reduced both overall fibrosis and septal area in adults with metabolic dysfunction-associated steatohepatitis (MASH) and compensated cirrhosis, based on a post hoc analysis ...

GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Piezo2 is increased in idiopathic pulmonary fibrosis (IPF). Immunohistochemistry of nonfibrotic (left) and IPF (right) lung tissue demonstrating that Piezo2 (brown staining) is strongly present in ...

The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices. In ...

Camilla Bell, M.Sc., Ph.D., an assistant professor in the UAB Department of Pathology’s Division of Molecular and Cellular Pathology, has been awarded a grant by Vertex Pharmaceuticals as part of the ...

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...